Acute Respiratory Distress Syndrome Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

Acute Respiratory Distress Syndrome Pipeline constitute 32+ key companies continuously working toward developing Acute Respiratory Distress Syndrome treatment therapies, analyzes DelveInsight

The report comprises Acute Respiratory Distress Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Acute Respiratory Distress Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Acute Respiratory Distress Syndrome pipeline products.

Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years. Key players, such as - Faron Pharmaceuticals, BioMarck Pharmaceuticals, Athersys, Apeiron Biologics, Cynata Therapeutics, Orbsen Therapeutics, GEn1E Lifesciences, Exvastat, Longeveron, CohBar, ZyVersa Therapeutics, Abbreos, Aviceda Therapeutics, ImStem Biotechnology, Bayer, AVM Biotechnology, Cartesian Therapeutics, Sage Therapeutics, Roivant Sciences, ZyVersa Therapeutics, Aerpio Pharmaceuticals, Apeiron Biologics, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment

The Acute Respiratory Distress Syndrome pipeline has been segmented and assessed based on various types of product.

Acute Respiratory Distress Syndrome Emerging therapies such as - HCR040, UMC 119 06, MultiStem cell therapy, AVM0703, ALT-100, CYP 001, BIO-11006, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years.

In August 2017, BioMarck Pharmaceuticals initiated the Phase IIa, placebo-controlled, multicenter pilot study to evaluate the safety and efficacy of BIO-11006 inhalation solution in patients with ARDS. In this study, the subjects were randomized 1:1 to either BIO-11006 125 mg twice daily plus standard of care or placebo plus standard of care. The trial got completed in March 2020 with 38 participants.

In April 2020, Athersys initiated an open-label, double-blinded, randomized, placebo-controlled PhaseII/III study to evaluate the safety and efficacy of MultiStem therapy in subjects with moderate to severe Acute Respiratory Distress Syndrome (ARDS) due to pathogens including COVID-19. The trial is currently in the recruiting stage with 400 participants and is estimated to be completed by January 2023.

In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA for the acute respiratory distress syndrome (ARDS) program. In May 2019, US FDA granted Fast Track designation to MultiStem cell therapy for ARDS.

Acute Respiratory Distress Syndrome Overview
Acute respiratory distress syndrome (ARDS) is a serious lung condition that causes low blood oxygen. People who develop Acute Respiratory Distress Syndrome (ARDS) are usually ill due to another disease or a major injury. In Acute Respiratory Distress Syndrome, fluid builds up inside the lungs' tiny air sacs, and surfactant breaks down. A surfactant is a foamy substance that keeps the lungs fully expanded so that a person can breathe. These changes prevent the lungs from filling properly with air and moving enough oxygen into the bloodstream and throughout the body. The lung tissue may scar and become stiff.

The goal of Acute Respiratory Distress Syndrome treatment is to improve oxygen levels and treat the underlying cause. Treatment focuses on supporting the patient while the lungs heal. The goal of supportive care is to get enough oxygen into the blood and deliver it to the body to prevent damage and remove the injury that caused Acute Respiratory Distress Syndrome to develop.

To know more about the Acute Respiratory Distress Syndrome treatment market, click here: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Respiratory Distress Syndrome Pipeline Therapies along with Key Players:
HCR040: Histocell
UMC 119 06: Meridigen Biotech
MultiStem cell therapy: Athersys
AVM0703: AVM Biotechnology
ALT-100: Aqualung Therapeutics
CYP 001: Cynata Therapeutics
BIO-11006: BioMarck Pharmaceuticals

Acute Respiratory Distress Syndrome Pipeline Market Drivers
Increasing R&D activities
Increasing incidence of Acute Respiratory Distress Syndrome
Non-competitive Landscape

Acute Respiratory Distress Syndrome Pipeline Market Barriers
Lack of awareness about the disease
Mechanical ventilation for management
Missed-diagnoses of Acute Respiratory Distress Syndrome

Further Central Retinal Vein Occlusion product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies at: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight

Coverage: Global

Key Acute Respiratory Distress Syndrome Companies: Faron Pharmaceuticals, BioMarck Pharmaceuticals, Athersys, Apeiron Biologics, Cynata Therapeutics, Orbsen Therapeutics, GEn1E Lifesciences, Exvastat, Longeveron, CohBar, ZyVersa Therapeutics, Abbreos, Aviceda Therapeutics, ImStem Biotechnology, Bayer, AVM Biotechnology, Cartesian Therapeutics, Sage Therapeutics, Roivant Sciences, ZyVersa Therapeutics, Aerpio Pharmaceuticals, Apeiron Biologics, and others

Key Acute Respiratory Distress Syndrome Therapies: HCR040, UMC 119 06, MultiStem cell therapy, AVM0703, ALT-100, CYP 001, BIO-11006, and others

Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies

Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers

Request for Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Assessment
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Acute Respiratory Distress Syndrome Report Introduction
2 Acute Respiratory Distress Syndrome Executive Summary
3 Acute Respiratory Distress Syndrome Overview
4 Acute Respiratory Distress Syndrome- Analytical Perspective In-depth Commercial Assessment
5 Acute Respiratory Distress Syndrome Pipeline Therapeutics
6 Acute Respiratory Distress Syndrome Late Stage Products (Phase II/III)
7 Acute Respiratory Distress Syndrome Mid Stage Products (Phase II)
8 Acute Respiratory Distress Syndrome Early Stage Products (Phase I)
9 Acute Respiratory Distress Syndrome Preclinical Stage Products
10 Acute Respiratory Distress Syndrome Therapeutics Assessment
11 Acute Respiratory Distress Syndrome Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Acute Respiratory Distress Syndrome Key Companies
14 Acute Respiratory Distress Syndrome Key Products
15 Acute Respiratory Distress Syndrome Unmet Needs
16 Acute Respiratory Distress Syndrome Market Drivers and Barriers
17 Acute Respiratory Distress Syndrome Future Perspectives and Conclusion
18 Acute Respiratory Distress Syndrome Analyst Views
19 Appendix
20 About DelveInsight

Request for Sample PDF Report, to know in detail about the Acute Respiratory Distress Syndrome clinical trial assessment - https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:
Acute Respiratory Distress Syndrome Market https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Acute Respiratory Distress Syndrome-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Acute Respiratory Distress Syndrome Epidemiology https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Acute Respiratory Distress Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Trending Reports:

Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.


Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.


Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027

To know more about our Competitive Services, Click here:
https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.